Evotec (ETR:EVT) Shares Up 3.5% – Still a Buy?

Evotec SE (ETR:EVT)’s share price shot up 3.5% during mid-day trading on Friday . The company traded as high as €4.76 and last traded at €4.70. 869,582 shares traded hands during trading, a decline of 36% from the average session volume of 1,360,000 shares. The stock had previously closed at €4.54.

Evotec Trading Up 3.5%

The company has a market cap of $872.06 million, a PE ratio of -5.08, a P/E/G ratio of 0.98 and a beta of 1.24. The stock’s 50 day moving average is €4.86 and its 200-day moving average is €5.50. The company has a quick ratio of 2.97, a current ratio of 1.68 and a debt-to-equity ratio of 55.38.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.